期刊文献+

百日咳毒素、丝状血凝素和黏附素的纯化 被引量:8

Purification of pertussis toxin,filamentous haemagglutinin and pertactin
原文传递
导出
摘要 目的采用新型层析介质对无细胞百日咳疫苗百日咳毒素(pertussis toxin,PT)、丝状血凝素(filamen-toushemagglutinin,FHA)和黏附素(pertactin,PRN)3组分进行分离纯化。方法调整PT和FHA发酵液上清的pH值和电导后,PT经Capto SP ImpRes和Capto MMC进行两步层析,FHA经Capto SP ImpRes进行一步层析;PRN热处理原液经Capto Adhere和Capto SP ImpRes进行两步层析。纯化产物经4%~12%NuPAGE进行鉴定,ImageQ分析纯度;LC-MASS(Thermo LTQ Velas)进行蛋白质的质谱检测;PT和FHA经BiaCore T200进行定量分析,并计算各步回收率。结果纯化后,无细胞百日咳疫苗3组分纯度均达95%以上;PT和FHA的总回收率均在30%左右;电泳图谱上的各组分条带经LC-MASS鉴定,均与Uniprot Bordetella pertussis数据库数据高度同源。结论采用新型层析介质有效纯化了无细胞百日咳疫苗PT、FHA和PRN,提高了抗原纯度,大大缩短了生产时间。 Objective To isolate and purify the pertussis toxin(PT),filamentous haemagglutinin(FHA)and pertactin(PRN)of acellular pertussis vaccine by using a novel chromatography medium.Methods The pH value and conductivity of fermentation liquid of PT and FHA were adjusted,based on which PT was purified by Capto SP ImpRes and Capto MMC chromatography,while FHA by Capto SP ImpRes chromatography.The purified samples were identified by 4% ~ 12% NuPAGE and analyzed for purity by ImageQ and for protein mass spectrum by LC-MASS(Thermo LTQ Velas).PT and FHA were analyzed quantitatively by BiaCore T200,and calucated for recovery rates at various steps.Results The purities of PT,FHA and PRN reached more than 95%.The total recovery rates of PT and FHA were about 30%.LCMASS showed high homologies of bands of the three components on electrophoretic profile to those in databank.Conclusion The PT,FHA and PRN components of acellular pertusis vaccine were purified effectively by novel chromatography media,while the antigen purities increased,and the time for production was shortened remarkably.
出处 《中国生物制品学杂志》 CAS CSCD 2013年第8期1186-1189,共4页 Chinese Journal of Biologicals
关键词 无细胞百日咳疫苗 百日咳毒素 丝状血凝素 百日咳黏附素 纯化 Acellular pertussis vaccine Pertussis toxin Filamentous haemagglutinin(FHA) Pertactin Purification
  • 相关文献

参考文献7

  • 1Wood N, Mclntyre P, Marshall H, et al. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age [J]. Pediatr Infect Dis J, 2010, 29 (3): 209-215. 被引量:1
  • 2Knuf M, Schmitt HJ, Wolter J, etal, Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants [J]. J Pediatr, 2008, 152 (5): 655-660. 被引量:1
  • 3Berger F, Njamkepo E, Minaberry S, et al. Investigation on a pertussis outbreak in a military school: risk factors and appro-ach to vaccine efficacy [J]. Vaccine, 2010, 28 (32): 5147- 5152. 被引量:1
  • 4Sato Y, Sato H. Development of acellular pertussis vaccines [J]. Siologicals, 1999, 27 (2): 61-69. 被引量:1
  • 5史久华.二十年来疫苗学十大进展[J].国外医学(预防.诊断.治疗用生物制品分册),2003,26(4):150-153. 被引量:1
  • 6谢广中.无细胞百日咳疫苗的发展及应用[J].上海预防医学,2006,18(1):6-8. 被引量:13
  • 7张庶民,徐颖华.我国百日咳疫苗现状及展望[J].中国药事,2005,19(11):685-688. 被引量:14

二级参考文献14

  • 1Plotkin SA. Jordan Report, 2002 ; 19-22. 被引量:1
  • 2Belshe RB et al. J Pediatr, 2002;136:168-175. 被引量:1
  • 3Leitner WW et al. Vaccine, 2002 ; 18 : 765-777. 被引量:1
  • 4Yuji Sato, Hiroko. Sato. Development of acellular pertussis vaccines[J]. Biologicals,1999,27(2): 61. 被引量:1
  • 5Mariagrazia. Pizza, Antonio. Ccvacci, Antonelia. Bartoloni,et al. Mutants of pertussis toxin suitable for vaccine development[J]. Science, 1989, 246 (4929): 497. 被引量:1
  • 6Kazunari, Kamachi. Toshifumi, konda. Yoshichika, Arakawa. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertusssi in mice[J]. Vaccine, 2003, 21 (31): 4609. 被引量:1
  • 7李忠明 张延龄 徐德启.当代疫苗学[M].北京:高等教育出版社,2001.257. 被引量:2
  • 8J. G. Kreeftenberg. Standardization of acellular pertussis vaccines[J]. Biologicals, 1999, 27(2): 115. 被引量:1
  • 9R. Parton. Review of the biology of bordetella pertussis[J]. Biologicals,1999,27 (2): 71. 被引量:1
  • 10World Health Organization. Make a difference[R]. The world health report,1999 ,(7):1. 被引量:1

共引文献23

同被引文献47

引证文献8

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部